Atossa Genetics to Present at 6th Annual LD Micro Invitational Conference on June 7th, 2016

SEATTLE, WA / ACCESSWIRE / May 31, 2016 / Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that Dr. Steven Quay, President and CEO, would be a featured presenter at the 6th annual LD Micro Invitational on June 7th, 2016 at 9:30am PST, Track 3 at the Luxe Sunset Hotel in Los Angeles, CA. Management will also be available for one-on-one meetings on June 7 and 8, 2016.

Registered attendees may request meetings through the Meetmax system through the following link: http://www.meetmax.com/sched/event_36833/invitee_login.html

View Atossa Genetics' Profile here: http://www.ldmicro.com/profile/atos

Profiles powered by LD Micro - News Compliments of Accesswire

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Atossa Genetics

Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact:

Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
(O) 800-351-3902
Kyle.Guse@atossagenetics.com

Investor Relations:
CorProminence LLC
Scott Gordon, President
(O) 516-222-2560
scottg@corprominence.com

SOURCE: Atossa Genetics, Inc. via LD Micro

ReleaseID: 440497

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.